Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Customers are to be offered discounted weight loss treatments through insurance giant Vitality in a UK first. The group, ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

They share what is becoming an open secret: They tried for years to control their weight but are now taking the new obesity drugs manufactured by Eli Lilly and Novo Nordisk. Dr. Robert Califf ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA ... provided a 47% greater relative weight loss compared to Wegovy® (semaglutide).

Frantic demand for drugs to treat obesity from Novo Nordisk, Eli Lilly, and others could support ... Mounjaro has generated stellar results in phase 3 weight-loss studies, achieving body weight ...

The FDA has said it has agreed to reconsider its decision to prevent compounding pharmacies from producing and selling versions of Eli ... weight-loss drugs, with Novo Nordisk and Lilly both ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Also Read: Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years In 2023, Eli Lilly acquired POINT Biopharma Global at $12.50 per share ...

But now there is good news for people taking weight loss medication who may be at risk. A new study indicates that the drug bimagrumab can counteract the side effects. Rapid weight loss affects ...

Researchers say patients shouldn’t randomly stop taking the drugs but doctors should be mindful that these medications are not the only options for controlling diabetes and weight loss.